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Abstract
Histamine receptors (HRs) are excellent drug targets for the treatment of diseases such as
schizophrenia, psychosis, depression, migraine, allergies, asthma ulcers, and hypertension. Among
them, the human H3 Histamine receptor (hH3HR) antagonists have been proposed for specific
therapeutic applications, including treatment of Alzheimer's disease, attention deficit hyperactivity
disorder (ADHD), epilepsy, and obesity.1 However, many of these drug candidates cause
undesired side effects through the cross-reactivity with other histamine receptor subtypes. In order
to develop improved selectivity and activity for such treatments it would be useful to have the
three dimensional structures for all four HRs. We report here the predicted structures of four HR
subtypes (H1, H2, H3, and H4) using the GEnSeMBLE (GPCR Ensemble of Structures in
Membrane BiLayer Environment) Monte Carlo protocol.2 sampling ~ 35 million combinations of
helix packings to predict the 10 most stable packings for each of the four subtypes. Then we used
these best 10 protein structures with the DarwinDock Monte Carlo protocol to sample ~
50,000*20 poses to predict the optimum ligand-protein structures for various agonists and
antagonists. We find that E2065.46 contributes most in binding H3 selective agonists (5, 6, 7) in
agreement with experimental mutation studies. We also find that conserved E5.46/ S5.43 in both
of hH3HR and hH4HR are involved in H3/ H4 subtype selectivity. In addition, we find that
M3786.55 in hH3HR provides additional hydrophobic interactions different from hH4HR (the
corresponding amino acid of T3236.55 in hH4HR) to provide additional subtype bias. From these
studies we developed a pharmacophore model based on our predictions for known hH3HR
selective antagonists in clinical study [ABT-239 1, GSK-189,254 2, PF-3654746 3, and BF2.649
(Tiprolisant) 4] that suggests critical selectivity directing elements are: the basic proton interacting
with D1143.32, the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups
interacting with lipophilic pockets in TMs 3-5-6 and the aliphatic ring located in TMs 2-3-7.
These 3D structures for all four HRs should help guide the rational design of novel drugs for the
subtype selective antagonists and agonists with reduced side effects.
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INTRODUCTION
Histamine receptors (HRs) are aminergic G protein-coupled receptors (GPCRs) with 7
transmembrane (TM)-spanning helices serving as a mediator in hypersensitivity (allergic)
responses, gastric acid secretion, neurotransmission, immunemodulation, cell differentiation,
and embryonic development, among others.3 Four subtypes of human HRs, H1, H2, H3, and
H4, have been identified.4 All HRs are excellent drug targets for the treatment of such
diseases as schizophrenia, Alzheimer's disease (AD), dementia, anxiety, tremor (Parkinson's
disease), attention deficit hyperactivity disorder (ADHD), mood disorders, sleep disorders
(narcolepsy), depression, migraine, allergies, asthma ulcers, stroke, epilepsy, obesity,
diabetes, and cancer.5 Indeed human histamine H1 receptor (hH1HR) antagonists
(antihistamine) are widely used in the treatment of allergy.6 In addition, hH2HR antagonists
are used in treating peptic ulcers, gastroesophageal reflux disease, and gastrointestinal
bleeding.7, 8 The hH3HR antagonists have been proposed for such therapeutic applications
as treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD),
epilepsy, and obesity.1 The hH4HR has been suggested as an interesting drug target for the
therapy of inflammation, allergy, and autoimmune disorders.9
While hH1HR, hH2HR, and hH4HRs have been successful targets of blockbuster drugs for
treating allergic diseases, gastric ulcer, and chronic constipation, the development of hH3HR
ligands still lag on their way to market, at least partly because of problems with selectivity.
Thus, we decided to focus on developing an understanding of how to make ligands selective
for hH3HR.
Section 1 in Results and Discussions describes the prediction of 3D structures for all four
subtypes (H1, H2, H3, and H4) of hHRs, using the GEnSeMBLE (GPCR Ensemble of
Structures in Membrane BiLayer Environment) method2 for generating the ensemble of the
10 most stable 3D structures of these GPCRs.
Then section 2 in Results and Discussions reports the predictions from the DarwinDock
method of the binding sites for structurally known antagonists 1, 2, 3, 4 now in clinical
studies, three agonists (5, 6, 7), five antagonists (clobenpropit 8 N'-[(4-
chlorophenyl)methyl]-1-[3-(3H-imidazol-4-yl)propylsulfanyl]formamidine, ciproxifan 9,
thioperamide 10, A-304121 [4-(3-((2R)-2-aminopropanoyl-1-
piperazinyl)propoxy)phenyl)cyclopropylmethanone] 11, A-317920 [N-((1R)-2-(4-(3-(4-
(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxo-ethyl-)-2-furamide]
12 for the structure-activity relationship (SAR) studies.10
The section 3 extends the comparison of the 3D structure of our predicted structure with the
recently reported 3.1 Å crystal structure of the hH1HR–T4-lysozyme fusion protein (H1R–
T4L) complex with doxepin.11 Since we predicted the 3D structure of all HRs when no x-
ray structure of the HRs was available, this comparison will validate our methods. The 1.3 Å
root mean squared deviation (RMSD) in TM between two structures reveals our atomic
details of binding site and model will be highly useful for guiding rational design of ligands
with high H3HR selectivity.
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RESULTS AND DISCUSSIONS
1. GEnSeMBLE predictions of apo-protein structures for all four HRs
The seven TM domains of 4 hHRs in Fig. 1 were predicted by PredicTM which combines
hydrophobicity analysis and multiple sequence alignment of sequences using the MAFFT12
program. Hydrophobic profile in the multiple sequence alignment (using the thermodynamic
and biological hydrophobic scales from White and von Heijne13, 14 shows all hHRs have 7-
TM characters as shown in GPCRs. hH2HR has a shorter intracellular 3 loop compared to
other subtypes. Fig. 2 shows the final TM regions and multiple alignments of all HRs from
PredicTM. All TM regions of four subtypes applied by capping rules are in good agreement
within 1 to 5 residue difference at the terminal end.
The GEnSeMBLE method2 was used to predict the 3D structure of all four HRs before the
x-ray structure of the H1HR was reported.11 In GEnSeMBLE we start with some template
structure and consider 12 rotations (30° pitch) about the helix axis for each of the 7 TM
regions, leading to (7)12 ~35 million packings. We then estimate the energy for all 35
million based on the pairwise interactions of the 12 strongly interacting pairs. In these
calculations we start with several experimental and computational templates and finally
select those with the best total interaction energies.
However when we started this project x-ray crystal structures were avaible for the human β2
adrenergic receptor (PDB: 2RH1)15 and the turkey β1 adrenergic receptor (PDB: 2VT4),16
Consequently we deviated from our standard methodology for predicting histamine receptor
structures as follows:
First, the TM regions in the two templates were identified and the corresponding regions in
the four histamine receptors identified based on the higher sequence homology in the TM
regions (Table S1). Overviews over which residues are part of the TM region for each of the
four HRs are shown in Table S2.
Then, each TM was mutated to match the HR of interest and energy-minimized in vacuous.
Then the 7 helix bundle was used as input to the BiHelix protocol of GEnSeMBLE2 in
which 144 combinations are considered for each pair each with re-optimized side chains.
Here, each of the seven TM was rotated systematically ±90° using a 15° sampling interval,
leading to structures for the packed bundle. Then we superimposed the BiHelix energies to
estimate the 1000 energetically most favored 7 TM helix bundles. These bundles were then
built, the side-chains re-optimized [using the SCREAM procedure17] and the total energies
were calculated using both the standard charged model (where Asp, Glu, Lys, Arg have net
charges) and neutral model we have developed.18 From these 1000 we collected the best 10
into Table 1 for each combination of HR and template. These results make it clear that for
hH1HR and hH3HR the structures derived from the human β2 adrenergic receptor were
significantly more favorable energetically than models derived from the turkey β1 adrenergic
receptor. In contrast, for hH2HR and hH4HR the structures derived from the turkey β1
adrenergic receptor were most favorable.
For these best 10 structures we examine new confituraitons including rotations of ±15° for
TM3, −15, ±30, 45° for TM4, 15° for TM5. We found that the structure derived directly
from the initial helix bundle (i.e. with η = 0° for all 7 helices) was not unreasonably high in
energy. This preference for structures near 0° supports the applicability of these two x-ray
crystal structures as a reasonable starting point for the BiHelix sampling. Indeed, the top-
scoring structures for all four HRs differed in the rotation of only a single one of the seven
TMs. For hH3HR the top-scoring model had a −30° rotation of TM4 (human β2 adrenergic
receptor as template), whereas for hH1HR the top-scoring model had a +15° rotation of TM4
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(human β2 adrenergic receptor as template). Moreover for hH2HR the top-scoring model had
a −15° rotation of TM4 (turkey β1 adrenergic receptor as template) while for hH4HR the
top-scoring model had a +15° rotation of TM5 (turkey β1 adrenergic receptor as template).
hH4HR has a sequence identity of 34.83% to hH3HR and 54.84% in TM region compared
with hH1HR (20.90% in overall, 32.15% in TM) and hH2HR (17.30% in overall, 33.08 in
TM) with low sequence identity in Table S1 in Supporting information. Many compounds
with reported affinity for hH3HR also have affinity for hH4HR. Compounds like clozapine,
clobenpropit behave as partial agonists at hH4HR and as antagonists at hH3HR showing
some functional selectivity.19 Many drug candidates cause undesired side effects through
their cross-reactivity. To develop improved selectivity and activity for such treatments we
use the 10 most stable three dimensional structures for all four HRs.
2. Predicted structures for ligands binding to all four HRs
First generation hH3HR antagonists were monoalkyl-substituted imidazole-based derivatives
like thioperamide, clobenpropit or ciproxifan.20 Potent stimulation of hH3HR has been
observed by imidazole derivatives only. Claimed interaction potential to CYP isozymes
caused by the imidazole moiety related to elements of the porphyrine cycle and sometimes
complex pharmacological behavior led to imidazole replacements. A general
pharmacophore element of these non-imidazole derivatives has been described which is
nowadays shown in numerous variations and combinations: A basic moiety is linked by a
spacer to a central, mostly aromatic core structure which then is connected to further affinity
enhancing elements, e.g. another basic moiety or hydrophilic/ lipophilic groups or a
combination thereof.21
A number of hH3HR antagonists have advanced to the clinical area for the potential
treatment of human cognitive disorders.22 These include 4-(2-{2-[(2R)-2-
Methylpyrrolidin-1-yl]ethyl}-benzofuran-5-yl)benzonitrile, (ABT-239 1), 6-[(3-
cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-Nmethyl-3-pyridinecarboxamide
hydrochloride (GSK189254 2), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-
ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746 3), 1-{3-[3-(4-
chlorophenyl)propoxy]propyl} piperidine hydrochloride (BF2.649 4), MK-0249 (structure
not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not
yet disclosed).
Among these, we selected structurally known compounds (structures shown in Chart 1) like
ABT-239 1 (pKi: 9.35 at hH3HR), for cognitive disorder (Phase I),23 GSK-189254A 2 (pKi:
9.59 at hH3HR) for dementia, narcolepsy, schizophrenia (Phase I),24 PF-3654746 3 (pKi:
8.49 at hH3HR) for allergic rhinitis (Phase II), and BF2.649 4 (tiprolisant, pKi: 8.3 at
hH3HR) for central nervous system disease: hypersommina, narcolepsy (Phase II)25 for
docking studies.
As summarized in Methods the DarwinDock method for predicting ligand binding sites,
starts by sampling the full protein to locate putative binding regions, and then aims at
sampling a complete set of ligand conformation (~20) for each of which we sample a
complete set of poses (~50,000), from which we select the best poses using the total binding
energy, E.
2.1 Endogenous agonist histamine—We docked histamine, the endogenous agonist 5,
to the lowest E predicted structure of hH3HR in Table 1 from CombiHelix.
Most of poses show salt-bridges at D1143.32 or E2065.46 with the protonated nitrogen atom
or the one of the nitrogen atoms in the imidazole ring. Our cavity analysis (Table 2) of the
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histamine bound to hH3HR shows that the major contributing amino acids in ligand binding
are E2065.46 (−5.08 kcal/mol), F2075.47 (−3.81 kcal/mol), Y1153.33 (−3.09 kcal/mol), and
D1143.32 (−2.12 kcal/mol) based on non-bonding energies [defined in the methods section
as the sum of vdW, electrostatic Coulomb with 2.5 dielectric constant and H-bond energies].
This result agrees with previous docking studies which all shows hydrophilic interactions at
D1143.32/ E2065.46 and hydrophobic interactions at Y1153.33, Y3746.51, and F3987.39 as
found in bovine rhodopsin based hH3HR homology models.26 Histamine has similar
interactions in hH4HR with the main interaction at D1143.32/ E2065.46.27, 28 Supporting this,
the Ala mutation of E2065.46 which was the most major contributing residue in the cavity
analysis (Table 2) shows dramatic loss of agonist with more than 2,000-fold decrease. In
addition, T204A5.44 and A202Q5.42 mutants display substantial decrease of histamine
binding with 5.7 and 4.2-fold decrease compared with the wild-type, respectively.26
In the neutral system of histamine-hH3HR, we find that the de-protonated nitrogen atom of
the histamine interacts with the protonated D1143.32, while the protonated E2065.46 also H-
bonds with the ε-NH atom in the imidazole ring of histamine, as shown in Fig. 3. An
additional hydrophobic interaction occurs at F2075.47 and Y1153.33.
2.2. hH3HR selective agonists, 5, 6, 7—We next matched the H3 selective agonist,
(R)-α-methyl histamine 6, to validate the binding site of histamine at hH3HR, leading to
common interactions at E2065.46 (−4.73 kcal/mol), F2075.47 (−3.99 kcal/mol), D1143.32
(−2.96 kcal/mol), and Y1153.33 (−2.38 kcal/mol). However, the stereoisomer, (S)-α-methyl
histamine 7, with ~100-fold less binding affinity reveals unfavorable interactions at
Y1153.33 (+6.84 kcal/mol) because of the bad contact with the α-methyl group (Table 3 and
Fig. 4). The result is a dramatic decrease in binding affinity (cavity sum = −18.07 for (R)-α-
methyl histamine 6 vs. −8.39 for (S)-α-methyl histamine 7) in agreement with the
dramatically decreased experimental binding affinity of (S)-α-methyl histamine 7 at hH3HR
(PKi at hH3HR: 8.2 for 6 vs 7.2 for 7).29
The cavity analysis of the H3 selective agonists (5, 6, 7) suggests the major contributing
amino acid is E2065.46 (Table 2 and 3). These docking results are in good agreement with
the current mutational study. The most pronounced reduction in potency and affinity of the
agonists was seen with the mutation of E2065.46.26
Thus the stereoselectivity of the methylated histamine derivatives are explained by these
docking studies. The result agrees with experimental observations, that the methylated
histamine derivative, (R)-α-methylhistamine is the more selective and the potent hH3HR
agonist. The (S)-stereo isomer is about 100 times less potent than the (R)-isomer.29
2.3 Docking of hH3HR selective antagonist 8, clobenpropit, at all four HRs and
further SAR studies—Antagonist docking started from the assumption that classical H3
antagonists such as monoalkyl-substituted imidazole-based derivatives would share the
interaction between their imidazole ring and E2065.46 as shown in the endogenous agonist,
histamine 5. This hypothesis is based on the partial structural similarity between histamine
and imidazole-containing H3 antagonists (i.e., the imidazole ring, the spacer, and the basic
or polar portion).
We docked hH3HR selective antagonist 8, clobenpropit, to the lowest E predicted structures
of all four hHRs of Table 1. From the cavity analysis of H3 subtype selective clobenpropit 8
bound to hH3HR, Table 4 shows that the major contributing amino acids are Y1153.33
(−4.96 kcal/mol), W4027.43 (−4.71 kcal/mol), and D1143.32 (−3.73 kcal/mol). The major H-
bonding is shown at D1143.32 and Y3746.51 with the isothiourea group. Additional H-
bonding with the terminal imidazole ring is formed at E2065.46. The para-chloro-benzyl
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group of clobenpropit 8 is surrounded by hydrophobic residues, L4017.42 and W4027.43, as
shown in Fig. 5.
To understand subtype selectivity, we matched the predicted best binding pose of the highly
H3-selective ligand clobenpropit 8 at hH3HR to other three subtypes (H1, H2, H4) of hHRs,
and then we used SCREAM17 to predict the optimum side chain position of residues in the
binding pocket, after which we minimized the final ligand/ protein complex post
neutralization. Predicted subtype residues that vary among four subtypes (H4: 29%, 8/28,
H1: 57%, 16/28, H2: 68%, 19/28) are displayed in Table 4. The corresponding amino acids
of conserved E5.46/ S5.43 in both of hH3HR and hH4HR are N1985.46/A1955.43 in hH1HR
and T1905.46/ G1875.43 (Fig. 2). Both of two subtype variable residues in hH1HR and
hH2HR show weakened interactions in the cavity in Table 4 and Fig. 6, resulting in a 2.2 to
2.4 kcal/mol favorable interaction in hH3HR. However, the similar interaction is shown at
these two conserved residues of hH4HR. Thus, the final cavity sum is a substantial decrease
in binding affinity (cavity sum = −34.11 in hH1HR, −33.77 in hH2HR) in agreement with
the dramatically decreased experimental binding affinity at hH1HR (PKi: 5.6) and hH2HR
(PKi: 5.2). The final cavity sum with the weakened binding affinity at hH4HR (PKi: 7.4) is a
−35.12 kcal/mol compared with the cavity sum of hH3HR (PKi: 9.4), −36.94 kcal/mol.
Thus, this predicted binding energy is consistent with the experimental binding affinity of
H3 subtype selective clobenpropit 8.30 The predicted structures were ordered by
experimental binding affinity including unified cavity energy (UniCav E) in Table 5 in all
subtypes of hHRs. Furthermore, all scoring energies at all HRs parallel with theirs
experimental binding affinities with the r2 values (correlation coefficients) of 0.67 to 0.99
(Fig. 6A).
For further SAR studies, we included four more antagonists, ciproxifan 9, thioperamide 10,
A-304121 11, and A-317920 12 in the same literature.30 Predicted binding cavity energies
for eight models in good agreement with experimental relative binding constants (r2=0.65
for all 8 and r2=0.93 for 6 excluding the flexible ligands, A-304121 11, and A-317920 12,
which include more than 10 rotatable bonds in their structures in Fig. 6). All of them share
the same binding site with major anchoring site at D1143.32 in Fig. 7.
Based on the docking studies of the subtype selective antagonist clobenpropit 8, we suggest
that E5.46/ S5.43 in hH3HR and hH4HR are involved in additional H-bonding interactions
with the terminal imidazole group in the monoalkyl-substituted imidazole-based derivatives,
however these interactions are lost in hH1HR and hH2HR, as shown in Fig. 7. Supporting
this, sequence alignments show that TM5 of the hHRs is poorly conserved, suggesting a
potential differences in the mechanism in which histamine binds to the hH3HR. For the
difference between hH3HR and hH4HR, M3786.55 in hH3HR (which is the corresponding
amino acid of T3236.55 in hH4HR) stabilizes through additional hydrophobic interactions
(−1.28 kcal/mol at M3786.55 vs −0.41 kcal/mol at T3236.55). Thus this predicted structure
explains the increase of H3 selectivity for clobenpropit 8 at hH3HR over the other three
subtypes.
In addition, scoring energy of hH3HR selective antagonist clobenpropit for all HRs
correlates with the observed experimental binding affinities with r2 values (correlation
coefficients) of 0.69 to 0.98. Docking studies were also carried out using structurally known
hH3HR selective antagonists in clinical trials, ABT-239 1, GSK-189,254 2, PF-3654746 3,
and BF2.649 4. The predicted 3D models should guide the rational design of novel drugs for
the subtype selective antagonists and agonists with reduced side effects. This excellent
agreement with current experimental studies, particularly the understanding of subtype
selectivity indicates that computationally derived structures of GPCRs can be sufficiently
accurate to develop subtype selective drugs that minimizes side effects.
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2.4 Docking of structurally known hH3HR selective antagonists in clinical
studies—To develop a general pharmacophore model for these non-imidazole derivatives
with hH3HR selectivity, we selected structurally known hH3HR targeting drugs in Phase I or
II pre-clinical studies, ABT-239 1 (pKi: 9.35), GSK-189254A 2 (pKi: 9.59), PF-3654746 3
(pKi: 8.49), and BF2.649 4 (tiprolisant, pKi: 8.3) for further docking studies.
As shown in Fig. 8, the binding sites of four antagonists are overlap, as expected. A central
basic moiety shows common H-bonding at D1143.32. An aromatic core structure leads to
further affinity enhancing elements, e.g. hydrophilic/ lipophilic groups is surrounded by
hydrophobic cavity in TMs 3-5-6 region. The aliphatic ring including a protonated nitrogen
is surrounded by another hydrophobic cavity in TMs 2-3-7. GSK-189254A 2 shows an extra
H-bond at S2035.43 with the nitrogen atom in the pyridine ring. PF-3654746 3 also forms
additional H-bonding interactions among the terminal amino group, Y1945.34, and E2065.46,
and between F substituent and Y3746.51.
All hH3HR selective antagonists could be mutually superposed following a common
pharmacophore model with similar arrangements at the same binding site. The proposed
pharmacophore model suggests the basic proton interacting with D1143.32, the spacer, the
aromatic ring substituted with the hydrophilic or lipophilic groups interacting with lipophilic
pockets in TMs 3-5-6 and the aliphatic ring located in TMs 2-3-7. This model is in good
agreement with the current generally accepted model; a basic amine motif separated by
several atoms from the central, typically hydrophobic, core, which is joined on the other side
by a structurally variable region in the form of another basic amine or a polar, non-basic
arrangement (e.g. amide).5
3. Structure comparison of predicted structure and the experimental x-ray structure of the
hH1HR (PDB ID: 3RZE).11
Compared to the crystal structure of the hH1HR, the RMSD of the predicted hH1HR
structure generated by our GEnSeMBLE method showed 1.33 Å RMSD in whole TMs, as
shown in Table 6. There were also no big differences with other subtypes in the average
backbone RMSD of TM helices with less than 1.64 Å for all three hH2HR (1.64 Å), hH3HR
(1.33 Å), and hH4HR (1.60 Å). The most similar structure of hH1HR is hH3HR with 0.04 Å.
Among TMs major structural deviations are shown at the TMs 1 and 5 with 0.85 and 0.84 Å
RMSD, respectively.
The recent availability of GPCR crystal structures provides some mechanistic insights into
both the inactive and active forms, which should be useful in designing ligands for
therapeutic applications. These results show that the seven-helix TM topology of these
receptors can exhibit multiple conformations with variations in interhelical orientations,
which in turn can change the binding site and energy of various ligands. These multiple
conformations are observed both for a given GPCR in different functional forms (e.g.,
inactive vs. active) and across different GPCRs. The conformational variations already
found in the crystallized GPCRs strongly suggest that homology models based on a single
template would not be sufficiently flexible to describe the multiple functional forms of a
receptor and would be unlikely to predict the important configurations of other GPCRs.
The GEnSeMBLE method applied in this paper was developed to enable exhaustive
sampling of the conformational space to sample the variety of packings explored by
receptors. We expect that this procedure dramatically increases the likelihood of predicting
accurate structures for functionally distinct conformations of a GPCR and for predicting the
structures of other more distant GPCRs. As additional GPCRs are crystallized to more fully
cover both sequence space and function space (through G protein or β arrestin coupled
pathways), such de novo prediction methods should increase in accuracy because of
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additional templates to initiate the process. Our results indicate that starting with a template
for a crystal for one subtype of a GPCR, we can obtain accurate structures for the other
subtypes. Also given a crystal structure of one GPCR we can obtain accurate structures for
other GPCRs that are within ~30% sequence identify for the TM regions.
CONCLUSIONS
We docking several H3 selective ligands to all four subtypes to determine the critical
components defining H3 subtype selectivity with respect to the other three subtypes obtained
by. Our predictions of the best conformations of the histamine at H1, H2, H3, and H4
receptors subtypes lead to several conclusions:
1. The largest contribution to binding of the H3 selective agonists (5, 6, 7) is E2065.46
in good agreement with the experimental mutational studies.
2. We find that the conserved E5.46/ S5.43 in both of hH3HR and hH4HR are
involved in H3/ H4 subtype selectivity through additional H-bonding with the
terminal imidazole group in the monoalkyl-substituted imidazole-based derivatives
but loss of these interactions in hH1HR and hH2HR. In addition, M3786.55 in
hH3HR is another subtype selective residue provides additional hydrophobic
stabilization different from hH4HR (the corresponding amino acid of T3236.55 in
hH4HR).
3. Our proposed pharmacophore model suggests that the residues important for
selectivity to hH3HR are:
• the basic proton interacting with D1143.32,
• the spacer,
• the aromatic ring substituted with the hydrophilic or lipophilic groups
interacting with lipophilic pockets in TMs 3-5-6 and
• the aliphatic ring located in TMs 2-3-7.
We expect our predicted 3D structures for all four HRs will help guide the rational design of
novel H3 subtype selective antagonists and agonists with reduced side effects. The excellent
agreement with current experimental studies, particularly the understanding of H3 subtype
selectivity indicates that computationally derived structures of GPCRs can be sufficiently
accurate to develop subtype selective drug to minimize side effects.
METHODS
We used the GEnSeMBLE method2 to predict the 3D structures for the various
conformations needed to understand the function of GPCRs and help design new ligands.
GEnSeMBLE provides a very complete sampling (millions to quadrillions) over possible
rotations and tilts, leading to a ensemble of low lying structures expected to include those
conformations energetically accessible for binding of ligands. This replaces our earlier
MembStruk method.31
We use the DarwinDock to predict the binding sites of ligands to the GPCRs. DarwinDock
samples ~ 20 conformations for ~50,000 poses expanding the predicted binding sites which
we consider to be a very complete sampling. DarwinDock replaces our earlier HierDock6
and MSCDock32 methods, providing a much more complete sampling of possible poses.
These earlier methods were validated by a series of applications to various GPCRs: human
D2 dopamine receptor (DR),33 human β2 adrenergic receptor,34, 35 human M1 muscarinic
receptor,36 human Chemokine (C-C) motif receptor 1 (CCR1),37 mouse MrgC11 (Mas
Kim et al. Page 8
J Chem Inf Model. Author manuscript; available in PMC 2012 December 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Related Gene) for the molluscan peptide FMRF-amide (FMRFa),38, 39 human prostanoid DP
receptor,40, human Serotonin 2C18 and human A2A adenosine41 receptor.
1. GEnSeMBLE41
The structure prediction methodology has been described previously41 so it will only be
briefly summarized here:
1) PredicTM: Uses multiple sequence alignment to predict the TM regions for
membrane protein.
2) OptHelix/Homologize: OptHelix generate helices with proper kinks (may be
caused by Prolines) using molecular dynamics. However when closely related x-
ray structures are available (as for the HRs), we find that Homology helices
often provide better helix shapes.
3) BiHelix: This algorithm samples all N7 packings of the 7 helices in a GPCR in
which N rotations about each helix are combine. Here we consider N=13, which
leads to ~63 million conformations. BiHelix partitions the 7-helix interaction
problem into 12 sets of BiHelix interactions, in which SCREAM17 is used to
optimize the side-chains for each combination.
4) CombiHelix: The BiHelix energies for all 63,000,000 packings are used to
select the best 1000. Then we build the full –helix bundle for each of these 1000
and optimize the side-chains for each using SCREAM. From this 1000 we select
an ensemble of ~10 lowest energy structures each of which is used in docking of
various ligands.
The Dreiding D3 force field (D3FF)42 was used throughout wherever energies were
evaluated.
2. Ligand docking
DarwinDock was used to dock several ligands to each of the lowest 10 predicted structures
of all 4 hHRs from BiHelix. The starting structure and charges of the ligands in Chart 1 were
calculated using density functional theory (B3LYP with the 6–311G** basis set).
Starting from the x-ray structure of histamine, we rotated the torsion angles N-Cal-Cal-Car by
60 ° increments to generate 6 conformations. These were generated with the Maestro
software and minimized with the D3FF. The final docked structure with the best binding E
from all ligand conformations was selected.
1) Scanning the receptor for potential binding regions—Starting with the predicted
structure, we predicted putative ligands binding regions as follows. We first alanized the
entire protein (replacing the 6 hydrophobic residues, I, L, V, F, Y, and W with A) and
scanned for potential binding regions with no assumption about the binding site. The entire
molecular surface of the predicted structure was mapped with spheres representing the
empty volume of the protein (currently using the Sphgen procedure in DOCK4.0 suite of
programs). The entire set of protein spheres was partitioned into ~30 to 50 overlapping
cubes of 10 to 14 Å sides. We then generated 1,000 poses for each of these 30 – 50 regions.
These results are compared to select the most promising two or three putative binding
regions.
2) DarwinDock—For each ligand conformation, we used DarwinDock to generate
iteratively ~50,000 poses spanning the putative binding regions of the bulky-residue-
alanized protein. These poses are partitioned into ~1200 to ~200 family head Voronai-like
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families based on RMSD. Then calculated the energies of the family heads and selected the
top 10% ordered by total energy. Then we calculated the binding energy for all the family
members of these top 10% family and selected the lowest energy 100 structures are chosen
for further optimization. For each of these 100 we dealanize the protein side-chains (using
SCREAM) to find the optimum side chains for each of the best 100 poses. Then we
neutralize the protein and ligand by transferring protons appropriately within salt bridges
and protonating or deprotonating exterior ligands, followed by further full geometry
minimization.
DarwinDock has been validated for a number of x-ray co-crystals including 3 crystal
structures of ligand/ GPCR complexes: human β2-adrenergic receptor (0.4 Å RMSD),15
human AA2AR (0.8 Å RMSD),43 and turkey β1-adrenergic receptor (0.1 Å RMSD).16 This
shows that DarwinDock can accurately identify ligand binding sites in proteins, which can
then be used to optimize the ligands with desirable properties.
3) Neutralization for scoring E—Quantum mechanics (QM) calculations show that for
an effective dielectric constant below 8, the extra proton on a Lys or Arg transfers back to
the negative carboxylate of an Asp or Glu. Thus we expect that buried salt bridges will have
neutral residues. We find that use of these neutral residue charges for the protein and ligand
improves the accuracy for comparing different docked structures. Of course the final bond
energy relative to ligand in the solvent and binding site exposed to solvent must be corrected
by the effective pKA of the ligand and of the exposed Lys, Arg, Glu, and Asp. For example,
if the pKA of a carboxylate is 4.5 and the solvent is taken to have a pH of 7.4, we must
correct by 2.9*1.38 kcal/mol.
For external residues not involved in binding, we also find it is expected to neutralize the
external residues exposed to solvent or membrane. Here the issue is that the force fields
commonly used in molecular dynamic calculations involve fixed charges, usually based on
QM. In reality any net partial charges are shielded by the dielectric polarization of the
surrounding protein and solvent so that there is negligible effect beyond 10Å. However with
fixed charges the electrostatic interaction energy between two point charges separated by
10Å is 33 kcal/mol. The result is that small changes in geometries of charged ligands far
from the binding site can lead to large differential binding energies, even 10 to 30 kcal/mol.
We find that neutralizing these exposed residues removes the sensitivity to details of the
distances of charged residues (and counter ions) remote from the active site. This
neutralization leads to differential binding energies that are dominated by the local cavity
interactions and leads to much smaller solvation energies.18
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BRIEFS
We report here the predicted structure of the human H3 Histamine receptor bound to
highly potent and selective H3 selective agonists and antagonists.
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Figure 1.
The hydropathy prediction from PredicTM for the four histamine receptors (HR).
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Figure 2.
Alignments of the four histamine (HR) subtypes, H1, H2, H3, and H4 from the PredicTM
method. The predicted transmembrane (TM) regions from PredicTM are displayed in
colored boxes (TM1 in purple, TM2 in blue, TM3 in cyan, TM4 in green, TM5 in yellow,
TM6 in orange, TM7 in red). Highly conserved residues in Family A G protein-coupled
receptors (GPCRs) are shown in red in TM 1–6 and white in TM7. Variable amino acids
among the four subtypes in the upper TM regions are marked with red asterisks and subtype
selective residues predicted from the cavity analysis are boxed. We use Ballesteros-
Weinstein numbering consisting of the TM helix number followed by residue number
relative to the highly conserved residue in the helix, numbered as 50. H-bonding is indicated
by arrows, and subtype selective residues are shown in red.
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Figure 3.
Predicted best models of the endogenous agonist histamine 5 bound to the human histamine
H3 receptor (hH3HR). The H-bonding is represented by the arrows with the distance
between the donor and the acceptor. The number with residue is from the order of unified
cavity E in Table 2. Schematic structure of the predicted binding sites is displayed in the
bottom figure.
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Figure 4.
Superposition of the H3 selective agonist (R)-α-methyl histamine 6 and (S)-α-methyl
histamine 7 to the human histamine H3 receptor (hH3HR). The H-bonding is represented by
the arrows between the donor and the acceptor. (S)-α-methyl histamine with ~ 100-fold less
binding affinity displayed unfavorable interaction at Y115 with α-methyl groups in red
arrow. The number with residue is from the order of unified cavity E in Table 3. Schematic
structure of the predicted binding sites is displayed in the bottom figure.
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Figure 5.
Predicted best models of the H3 selective antagonist clobenpropit 8 bound to the human
histamine H3 receptor (hH3HR). The H-bonding is represented by the arrows between the
donor and the acceptor. The number with residue is from the order of unified cavity E in
Table 5. Schematic structure of the predicted binding sites is displayed in the bottom figure.
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Figure 6.
The predicted binding energies (kcal/mol) to the H3 selective antagonist clobenpropit 8
bound to four human histamine receptors (hH1HR, hH2HR, hH3HR, hH4HR) and other
antagonists, ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 at hH3HR listed
in Table 5 compared with the experimental binding constants (pKi). The dotted line shows
the fit without two outliers, 11 and 12, (which is much more flexible than the others).
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Figure 7.
Predicted best models of the H3 selective antagonist clobenpropit 8 bound to four human
histamine receptors (hH1HR, hH2HR, hH3HR, hH4HR) and other antagonists, ciproxifan 9,
thioperamide 10, A-304121 11, and A-317920 12 at hH3HR. H-bonding is indicated by red
dots, and subtype selective residues are shown in red.
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Figure 8.
Predicted binding sites of structurally known human histamine H3 receptor (hH3HR) in
clinical study, ABT-239 1, GSK-189,254 2, and PF-3654746 3, and BF2.649 (Tiprolisant) 4
at hHH3R. H-bonding is indicated by red dots.
Kim et al. Page 22
J Chem Inf Model. Author manuscript; available in PMC 2012 December 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chart 1.
The chemical structures of structurally known histamine H3 receptor antagonists in clinical
study, ABT-239 1, GSK-189254A 2, PF-3654746 3, and BF2.649 (Tiprolisant) 4. Binding
affinities (pKi) are shown for H3 with its function in parenthesis compared to the
endogenous histamine.
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